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Sir,
We read with interest the article by Kim et al (2014) , highlighting important challenges in pre-operative lymph node staging in early-stage cervical cancer.
From our point of view the article warrants further debate: (a) First question: Is there really a commitment to offer lymphadenectomy to all women with early-stage cervical cancer? (b) Second question: Is there an algorithm or nomogram to assess the nodal risk involvement to better select women who can really benefit from retroperitoneal surgical staging? (c) Third question: What is the impact of those tools in the decision-making process in women desiring to preserve fertility?
Presence of nodal metastasis is one of the most important risk factors for recurrence in surgically treated patients with early-stage cervical cancer (Sevin et al, 1995) . The incidence of pelvic lymph node metastasis in stage IB cervical cancer ranges from 11.5 to 21.7% (Morice et al, 1999; Gien and Covens, 2009 ).
In the series of Kim et al (2014), 81.6% of patients were diagnosed with cervical cancer with a low risk for nodal involvement. In such patients, PET/ CT seems to have limited impact as it is not sensitive enough to assess lymph node status.
PET/CT has a spatial resolution limit equal to or lower than 5 mm, and considering its low sensitivity for detection of lymph node metastasis, in our opinion, it seems to have a limited impact on the management of early-stage cervical cancer patients with tumour size smaller than 4 cm.
In a previous series of selected early-stage cervical cancer patients (n ¼ 159), we found a rate of nodal metastases of 8% in women with clinical tumour size less than 2 cm, and 34% in women with tumour diameter 2-4 cm. In this low-risk population 56% of lymph node-positive patients (34 of 61) demonstrated nodal metastatic deposits o5 mm. PET/CT sensitivity and negative predictive values (NPVs) were 32.1 and 69.2%, respectively (Signorelli et al, 2011) .
In our recent study (Crivellaro et al, 2012) , we found the mean MTV (Metabolic Tumour Volume) of patients with tumours clinically larger than 2 cm to be significantly higher (17.0 ml) than that of patients with smaller tumours (6.4 ml), and the rate of nodal metastases in the first and second groups was 33 and 9%, respectively.
Sentinel node (SN) biopsy has gained attention, because emerging data from retrospective studies have highlighted its prognostic impact on survival from micrometastases (Gortzak-Uzan et al, 2010) . A recent study (Cibula et al, 2012) confirmed preliminary data in a large cohort of 645 patients with early-stage cervical cancer undergoing surgical treatment, including SN biopsy. The presence of micrometastasis in SN was associated with significantly reduced overall survival, which corresponded to the survival in patients with macrometastasis.
This scenario underlines the importance of micrometastasis in early-stage disease, raising important considerations for the subgroup of young women candidates for conservative treatment, in whom identification of algorithms and pre-operative nomograms incorporating SN should be useful.
In our Department, women with tumours greater than 2 cm (stage 1B1-IIA1) with negative nodal involvement after pelvic lymphadenectomy and SN mapping are offered neoadjuvant chemotherapy with three cycles of TIP (Cisplatin, Ifosfamide and Paclitaxel). In cases of optimal pathologic response (CR þ PR1) we perform a simple trachelectomy.
Because micrometastasis seems to be an independent prognostic factor for survival in early-stage disease, and considering that negative pre-operative workup for nodal metastasis still has a high false-negative rate, SN mapping must be incorporated in fertility-sparing surgery.
In case of bulky disease, achievement of an optimal pathologic response after neoadjuvant chemotherapy seems to be a strong independent predictor of survival even in conservative approach (Marchiole et al, 2011) ; therefore, considering the higher risk for relapse, in case of suboptimal response (PR2 o more) we omit a conservative approach in favour of radical surgery.
The debate on whether or not to perform radical lymphadenectomy in early cervical cancer appears strange, considering the outcome in breast cancer, as the publication of the results of Z0011 showed no outcome differences between axillary dissection and no further axillary surgery in patients with positive SN, raising doubts on the role of SN biopsy. The SOUND randomised trial comparing SN biopsy with mere observation in patients with a negative axillary ultrasound who are small breast cancer candidates for breast-conserving surgery is ongoing at the European Institute of Oncology of Milan (Gentilini and Veronesi, 2012) .
Prospectively, application of integrated imaging and SN algorithms could be 'traded-off' between no nodal dissection and systematic lymphadenectomy in patients with early-stage cervical cancer, minimising morbidity and the false-negative rate of SN mapping and tailoring the treatment of patients with early-stage cervical cancer.
We would like to thank Buda et al, 2014 for their valuable comments on our study. They make three comments. First, is there really a commitment to offer lymphadenectomy to all women with early-stage cervical cancer? Second, is there an algorithm or nomogram to assess the nodal risk involvement to better select women who can really benefit from retroperitoneal surgical staging? Finally, what is the impact of those tools in the decision making in women desiring to preserve fertility?
So far, pelvic lymphadenectomy is endorsed as a standard surgical procedure in early-stage cervical cancer including stage IA1 disease with lymphovascular space invasion (Koh et al, 2013) . However, B80% of earlystage cervical cancer patients are node-negative and the therapeutic effect of lymphadenectomy in these patients is still controversial. Some authors suggested that among node-negative patients survival is improved when a greater number of lymph nodes are removed because of better extraction of micrometastasis (Shah et al, 2011) . Therefore, lymphadenectomy in earlystage cervical cancer should be offered until clinical trials elucidate the therapeutic value of lymphadenectomy in node-negative disease.
It is clear that patient selection for such trials is the critical issue. The results of our study show accurate identification of the low-risk group of LNM and we believe it could help patients' stratification in designing such trials. Although our nomogram is dependent on the status of lymph node detected by PET/CT, the other two factors (age and tumour size) are incorporated into the model to compensate the false-negative findings of PET/CT. As Buda et al, 2014 commented, PET/CT sensitivity and negative predictive values seem to be low in the early-stage cervical cancer patients with tumour size o4 cm (Signorelli et al, 2011) , although PET/CT is the most accurate imaging tool for assessment of nodal status in cervical cancer currently. After review of our data set comprising a model development cohort with tumour size o4 cm (n ¼ 248), PET/CT sensitivity and negative predictive values were 63.9% and 93.5%, respectively. We believe the main reason for the difference in this subgroup could be the different proportions of micrometastasis (defined as metastatic deposits o5 mm). Of the 36 cervical cancer node-positive patients, 14 (39%) patients showed micrometastases in our data set, whereas 56% nodepositive patients (34/61) demonstrated micrometastases in previous series of Buda et al, 2014 We agree with Buda's opinion that metabolic tumour volume (MTV) correlates with lymph node metastasis. In our recent study of 84 endometrial cancer patients, the group with MTV Z17.15 ml was significantly associated with lymph node metastasis (Shim et al, 2014) . Using this volumetric functional parameter or combining sentinel lymph node (SLN) biopsy could lead to improvement in our model.
To confer the benefits of SLN biopsy to patients who desire to preserve fertility, a careful preoperative evaluation for eligible patients is important. Although SLN biopsy may be useful for avoiding complete lymphadenectomy, its routine clinical use is still limited because of technical difficulties and prerequisites such as a nuclear medicine department, intraoperative frozen sections, and ultrastaging. In addition, SLN detection rate was reported to be associated with tumour size and preoperative conisation; SLN detection rate was statistically lower in patients with tumour sizes 43 cm (Du et al, 2011) and those with conisation (Dargent and Enria, 2003; Seong et al, 2007) . Thus, SLN biopsy would be useful for detecting nodal metastasis in small-volume tumour, and using imaging modalities such as PET/CT would be useful in other cases. In this regard, the nomogram conjuncted with SLN biopsy would be clinically helpful for selecting appropriate patients who wish to preserve fertility and could be treated with radical trachelectomy.
As suggested by Buda et al, 2014, we think that SLN biopsy is of great value in early cervical cancer patients, especially in those with small-size tumor. However, its clinical use is still limited because of technical difficulties and lack of standardisation. Our developed nomogram is a non-invasive, easily applicable, and user-friendly tool. We believe that the nomogram will allow selection of a patient population at low risk for nodal metastasis and thus facilitate the design of clinical trials. Definitely, as suggested by Buda et al, 2014 , assessment of nodal status solely by PET/CT still represents a challenge and the nomogram requires rigorous validation. Thus, future researches should focus on testing whether the predictive performance can be shown in other independent cohorts and enhanced by incorporating SLN biopsy.
